iX Biopharma FY2026 Results Show Strategic Pivot To US Markets

This episode explores how iX Biopharma Ltd transformed its business model during FY2026 by shifting its commercial focus from Australian medicinal cannabis to the lucrative US healthcare market. We examine the bold decisions, regulatory milestones and massive growth catalysts that are completely reshaping the company's financial future.   • The military breakthrough and the sole-source contract driving a massive strategic pivot   • The Australian headwinds and import permit delays that prompted this dramatic geographical redirection   • The onshore manufacturing transition to establish a US presence and bypass prospective import tariffs Visit BackgroundBriefing for SGX news, written analysis and more Follow us on LinkedIn